Basilea Pharmaceutica Ltd. Logo
 
Home
 
 
Search
 
 
 

Basilea Pharmaceutica Ltd. is headquartered in Basel, Switzerland, and listed on the SIX Swiss Exchange (SIX: BSLN). Through its fully integrated research and development operations the company focuses on the development of innovative antibiotics, antifungals and oncology drugs, targeting the medical challenge of resistance and non-response to current treatment options.

 
News
 
 
Language
 
Monday, June 27. 2016
 
Basel, Switzerland, June 27, 2016 - Basilea Pharmaceutica Ltd. (SIX: BSLN) announces that it has launched its new azole antifungal CRESEMBA® (isavuconazole) in Italy and will sponsor today a continuing medical education event on current challenges and recent developments in the management of invasive fungal infections in Bologna, Italy. The event will be co-chaired by Prof. Claudio Viscoli MD, Professor of Infectious Diseases, University of Genova and Prof. Corrado Girmenia MD, Professor of Haematology, Sapienza University of Rome.
 
more...
 
Thursday, June 09. 2016
 
  • Clinical data reported from completed phase 1/2a study of BAL101553, with once-weekly 2-hour infusion showing signals of clinical activity
  • Design of ongoing phase 1/2a study with once-daily oral BAL101553 presented, with four dose cohorts completed
  • Design of ongoing BAL3833 oral phase 1 study presented, with four dose cohorts completed
 
more...
 
Thursday, April 21. 2016
 
Basel, Switzerland, April 21, 2016 - Basilea Pharmaceutica Ltd. (SIX: BSLN) reported that the shareholders approved all agenda items proposed by the Board of Directors at today's Ordinary General Meeting of Shareholders (AGM) for the financial year 2015. At the meeting, 33.2 percent of Basilea's share capital was represented.
 
more...
 
Thursday, April 21. 2016
 
  • Tumor checkpoint controller BAL101553 demonstrates pre-clinical activity in treatment-refractory glioblastoma models as single agent and in combination treatment
  • PanRAF/SRC kinase inhibitor BAL3833 inhibits tumor growth in preclinical KRAS-driven cancer models
 
more...
 
Info
 
 
 

Quick links:

Investor calendar
Upcoming events
 


News subscription
Press releases via e-mail
 


French Sunshine Act
Transparence des liens d’intérêt